Uridisitol 2 Mg 30 Tablets

• • Competitive antagonist of muscarinic receptors (M2 and M3) in detrusor muscle; active 5-hydroxymethyl metabolite contributes to effect.
  • Inhibits involuntary bladder contractions, increases functional bladder capacity, delays initial urge and reduces urgency episodes.

Dosage & Administration

• • Standard Dose: 2 mg twice daily (1 tablet BID).

• • Reduced Dose: 1 mg twice daily (use in renal impairment CrCl ≤30 mL/min, moderate hepatic impairment, elderly with comorbidities, or when combined with potent CYP3A4 inhibitors).

• • Administration: With or without food; follow prescriber instructions.

Indications (SFDA Approved)

• • Urinary Urgency: Sudden compelling desire to pass urine difficult to defer.

• • Urge Incontinence: Involuntary leakage accompanied by or immediately preceded by urgency.

• • Urinary Frequency: ≥8 voids/24h.

• • Nocturia: Waking ≥1 time/night to void with impact on sleep.

Contraindications & Precautions

• • Absolute contraindications: Hypersensitivity to tolterodine/excipients, urinary retention, uncontrolled narrow-angle glaucoma, myasthenia gravis, severe ulcerative colitis/toxic megacolon.

• • Use with caution: Bladder outflow obstruction, GI disorders, renal/hepatic impairment, autonomic neuropathy.

• • Pregnancy/Lactation: Not recommended — insufficient human data.

Safety Profile & Adverse Events

• • Very common (≥10%): Dry mouth (≈35%).

• • Common (1–10%): Headache (12%), constipation (7%), dizziness (5%), abdominal pain (5%), dry eyes (3%), fatigue (4%).

• • Serious/rare: Urinary retention (<1%), cognitive impairment (rare, elderly), cardiac arrhythmias (very rare).